<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22848478</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.</ArticleTitle><Pagination><StartPage>e41381</StartPage><MedlinePgn>e41381</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e41381</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0041381</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is responsible for hand, foot and mouth disease with high mortality among children. Various neutralizing B cell epitopes of EV71 have been identified as potential vaccine candidates. Capsid-incorporation of antigens into adenovirus (Ad) has been developed for a novel vaccine approach. We constructed Ad3-based EV71 vaccine vectors by incorporating a neutralizing epitope SP70 containing 15 amino acids derived from capsid protein VP1 of EV71 within the different surface-exposed domains of the capsid protein hexon of Ad3EGFP, a recombinant adenovirus type 3 (Ad3) expressing enhanced green fluorescence protein. Thermostability and growth kinetic assays suggested that the SP70 epitope incorporation into hypervariable region (HVR1, HVR2, or HVR7) of the hexon did not affect Ad fitness. The SP70 epitopes were thought to be exposed on all hexon-modified intact virion surfaces. Repeated administration of BALB/c mice with the modified Ads resulted in boosting of the anti-SP70 humoral immune response. Importantly, the modified Ads immunization of mother mice conferred protection in vivo to neonatal mice against the lethal EV71 challenge, and the modified Ads-immunized mice serum also conferred passive protection against the lethal challenge in newborn mice. Compared with the recombinant GST-fused SP70 protein immunization, immunization with the Ads containing SP70 in HVR1 or HVR2 elicited higher SP70-specific IgG titers, higher neutralization titers, and conferred more effective protection to neonatal mice. Thus, this study provides valuable information for hexon-modified Ad3 vector development as a promising EV71 vaccine candidate and as an epitope-delivering vehicle for other pathogens.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xingui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou Medical College, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Xiaobo</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haitao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ting</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhichao</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Tianhua</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Rong</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>PLoS One. 2012;7(10). doi:10.1371/annotation/2da932d4-8654-45c8-bf83-7b3b09dbc146</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="Y">Adenoviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22848478</ArticleId><ArticleId IdType="pmc">PMC3407240</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0041381</ArticleId><ArticleId IdType="pii">PONE-D-12-02650</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong KT, Lum LC, Lam SK (2000) Enterovirus 71 infection and neurologic complications. N Engl J Med 342: 356&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10660401</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Stratov I, Nagarajan L, Davis S (2001) Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32: 236&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">11170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY (2007) Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics 120: e244&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, et al. (2009) Enterovirus 71 outbreak in the People&#x2019;s Republic of China in 2008. J Clin Microbiol 47: 2351&#x2013;2352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, et al. (2002) Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 46: 621&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12437029</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert GL, Dickson KE, Waters MJ, Kennett ML, Land SA, et al. (1988) Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 7: 484&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">2841639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Lu J (2010) Enterovirus 71 vaccine: close but still far. Int J Infect Dis 14: e739&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110504</ArticleId><ArticleId IdType="pubmed">20400350</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, et al. (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125: 61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Mao C, Ma S, Wang X, Sun Z, et al. (2009) Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390: 1126&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">19799860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">12900280</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW (2010) Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 16: 3149&#x2013;3157.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687873</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: 404&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">17473845</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH (2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5: 386&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967414</ArticleId><ArticleId IdType="pubmed">20978378</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Farina JB, Meshack S, Santovena A, Patel S, et al. (2010) Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer. Endocrine 37: 430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">20960164</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones FR, Gabitzsch ES, Xu Y, Balint JP, Borisevich V, et al. (2011) Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29: 7020&#x2013;7026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578229</ArticleId><ArticleId IdType="pubmed">21821082</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews QL (2011) Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm 8: 3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034826</ArticleId><ArticleId IdType="pubmed">21047139</ArticleId></ArticleIdList></Reference><Reference><Citation>Crompton J, Toogood CI, Wallis N, Hay RT (1994) Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75 (Pt 1): 133&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">7509367</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui H, Sakurai F, Kurachi S, Tashiro K, Sugio K, et al. (2009) Development of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob. Gene Ther 16: 1050&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">19516278</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, et al. (2006) Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 80: 5523&#x2013;5530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472137</ArticleId><ArticleId IdType="pubmed">16699033</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625206</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell MJ, Danthinne X, Imperiale MJ (2006) Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol 80: 5361&#x2013;5370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472126</ArticleId><ArticleId IdType="pubmed">16699016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, et al. (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79: 3382&#x2013;3390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1075677</ArticleId><ArticleId IdType="pubmed">15731232</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews QL, Fatima A, Tang Y, Perry BA, Tsuruta Y, et al. (2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5: e11815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910733</ArticleId><ArticleId IdType="pubmed">20676400</ArticleId></ArticleIdList></Reference><Reference><Citation>Youil R, Toner TJ, Su Q, Chen M, Tang A, et al. (2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13: 311&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">11812286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, et al. (2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76: 12775&#x2013;12782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136697</ArticleId><ArticleId IdType="pubmed">12438602</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M (2010) Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120: 3688&#x2013;3701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947213</ArticleId><ArticleId IdType="pubmed">20811151</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Su X, Seto D, Zheng BJ, Tian X, et al. (2009) Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 27: 1145&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146906</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone D, Liu Y, Li ZY, Tuve S, Strauss R, et al. (2007) Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol Ther 15: 2146&#x2013;2153.</Citation><ArticleIdList><ArticleId IdType="pubmed">17895860</ArticleId></ArticleIdList></Reference><Reference><Citation>Short JJ, Vasu C, Holterman MJ, Curiel DT, Pereboev A (2006) Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res 122: 144&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2203219</ArticleId><ArticleId IdType="pubmed">16920215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, et al. (2004) The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 78: 4454&#x2013;4462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387694</ArticleId><ArticleId IdType="pubmed">15078926</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford-Miksza L, Schnurr DP (1996) Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 70: 1836&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190011</ArticleId><ArticleId IdType="pubmed">8627708</ArticleId></ArticleIdList></Reference><Reference><Citation>Rux JJ, Kuser PR, Burnett RM (2003) Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77: 9553&#x2013;9566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187380</ArticleId><ArticleId IdType="pubmed">12915569</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, et al. (2007) Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 81: 1680&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1797575</ArticleId><ArticleId IdType="pubmed">17108028</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Qu Z, Wu X, Wang Y, Liu L, et al. (2009) Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein. Vaccine 27: 5103&#x2013;5110.</Citation><ArticleIdList><ArticleId IdType="pubmed">19573641</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, et al. (2008) Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5: 98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2535600</ArticleId><ArticleId IdType="pubmed">18718011</ArticleId></ArticleIdList></Reference><Reference><Citation>Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115: 1281&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1070634</ArticleId><ArticleId IdType="pubmed">15841217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzi A, Ben Youssef G, Perricaudet M, Benihoud K (2011) Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid. Vaccine 29: 1463&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pubmed">21184856</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Macary PA, Alonso S, Poh CL (2008) Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol 21: 215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18419256</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, et al. (2011) Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6: e20005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al. (2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28: 7444&#x2013;7451.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, Wong KT (2010) Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: 661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia CS, Liu JN, Li WB, Ma CM, Lin SZ, et al. (2010) The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J 7: 47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839975</ArticleId><ArticleId IdType="pubmed">20170551</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29: 4362&#x2013;4372.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, et al. (2004) Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 85: 2981&#x2013;2989.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ar&#xe9;valo MT, Xu Q, Paton JC, Hollingshead SK, Pichichero ME, et al. (2009) Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunology &amp; Medical Microbiology 55: 346&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">19291171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC (2009) Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 7: 735&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10: 778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al. (2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, Su X, Li H, Li X, Zhou Z, et al. (2011) Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res 160: 214&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21740937</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>